A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

American Journal of Psychiatry

Volumn 158, Issue 5, 2001, Pages 765-774

  Conley, Robert R ^a   Mahmoud, Ramy ^b  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; RISPERIDONE;

ADULT; ANXIETY; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOIDISM; SCHIZOPHRENIA; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZODIAZEPINES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PIRENZEPINE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0035002177     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.158.5.765     Document Type: Article

References (28)

1. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13:25-40
2. Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825-835
3. Marder SR, Davis JM, Chouinard G: The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997; 58:538-546
4. Beasley CM Jr, Tollefson GD, Tran P, Satterlee W, Sanger T, Hamilton S (Olanzapine HGAD Study Group): Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14:111-123
5. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154:457-465
6. Kane JM: Pharmacologic treatment of schizophrenia. Biol Psychiatry 1999; 46:1396-1408
7. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Anderson SW, Beasley C Jr, Tollefson GD: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17:407-418
8. Schooler NR: Comments on article by Tran and colleagues, "Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders" (letter). J Clin Psychopharmacol 1998; 18:174-176
9. Gheuens J, Grebb JA: Comments on article by Tran and colleagues, "Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders" (letter). J Clin Psychopharmacol 1998; 18: 176-179
10. Kasper S, Kuefferle B: Comments on "Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders" by Tran and associates (letter). J Clin Psychopharmacol 1998; 18:353-356
11. Ho BC, Miller D, Nopoulos P, Andreasen NC: A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J Clin Psychiatry 1999; 60:658-663
12. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276
13. Chouinard G, Ross-Chouinard A, Annable L, Jones BD: Extrapyramidal Symptom Rating Scale (abstract). Can J Neurol Sci 1980; 7:233
14. National Disease and Therapeutic Index. Plymouth Meeting, Penn., IMS America, June 1999
15. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156:286-293
16. Kasper S: Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia. Int Clin Psychopharmacol 1998; 13:253-262
17. National Institutes of Health, National Lung, Heart and Blood Institute: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. NIH Publication 98-4083. Bethesda, Md, National Institutes of Health, 1998
18. Osser DN, Najarian DM, Dufresne RL: Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999; 60: 767-770
19. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC: Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44:778-783
20. Goldstein LE, Sporn J, Brown S, Kim H, Finkelstein J, Gaffey GK, Sachs G, Stern TA: New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999; 40:438-443
21. Gatta B, Rigalleau V, Gin H: Diabetic ketoacidosis with olanzapine treatment. Diabetes Care 1999; 22:1002-1003
22. Rosengren A, Wedel H, Wilhelmsen L: Body weight and weight gain during adult life in men in relation to coronary heart disease and mortality: a prospective population study. Eur Heart J 1999; 20:269-277
23. Beasley CM Jr: Safety of olanzapine. J Clin Psychiatry Monogr 1997; 15:19-21
24. Gupta S, Droney T, Al-Samarrai S, Keller P, Frank B: Olanzapine-induced weight gain (letter). Ann Clin Psychiatry 1998; 10:39
25. Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M: Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999; 19:57-61
26. Dickson RA, Dalby JT, Williams R, Edwards AL: Risperidone-induced prolactin elevations in premenopausal women with schizophrenia (letter). Am J Psychiatry 1995; 152:1102-1103
27. Popli A, Gupta S, Rangwani SR: Risperidone-induced galactorrhea associated with prolactin elevation. Ann Clin Psychiatry 1998; 10:31-33
28. Dickson RA, Glazer WM: Hyperprolactinemia and male sexual function (letter). J Clin Psychiatry 1999; 60:125